Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for March 8, 2022

3/8/2022

 
Regulatory Update
 
The FDA approved ciltacabtagene autoleucel (Carvykti, Johnson & Johnson and Legend Biotech), on 2/28/2022, for the treatment of patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. 
  • Ciltacabtagene autoleucel was approved with a black box warning for cytokine release syndrome, neurotoxic events, prolonged cytopenias , hemophagocytic lymphohistiocytosis/macrophage activation syndrome, Parkinsonism and Guillain-Barré syndrome. 
  • J&J and Legend have set WAC at $465,000. Ciltacabtagene autoleucel is only available through a Risk Evaluation and Mitigation Strategy (REMS) called the CARVYKTI REMS.
The FDA approved pacritinib (Vonjo, CTI BioPharma), on 2/28/2022, to treat intermediate or high-risk primary or secondary myelofibrosis with severe thrombocytopenia (post-polycythemia vera or post-essential thrombocythemia).
 
The FDA rejected lenacapavir due to concerns of the incompatibility of vials made of borosilicate glass with lenacapavir solution, which could potentially lead to the formation of sub-visible glass particles. Gilead plans to resubmit the NDA with a different vial type.
 
The FDA designated Pfizer’s investigational respiratory syncytial virus (RSV) vaccine, PF-06482077, a Breakthrough Therapy for prevention of RSV-associated lower respiratory tract illness in infants from birth up to six months of age by active immunization of pregnant women.
 
Announced Research Updates
 
Vaccine efficacy for PF-06425090 Clostridium difficile vaccine to prevent Clostridioides difficile in adults 50 years of age and older.
 
AP-013 effect on the WOMAC pain and function scores in patients with severe osteoarthritis of the knee.
 
Safety of fezolinetant on endometrial health in patients with moderate to severe vasomotor symptoms associated with menopause.
 
Published Research Updates
 
Effect of roluperidone on the PANSS-derived Negative Symptoms Factor Score in patients with schizophrenia presenting with moderate to severe negative symptoms.
 
Nirsevimab efficacy in preventing RSV-associated lower respiratory tract infection and hosptializations in healthy late preterm and term infants of 35 weeks or greater gestational age
 
The results form adding toripalimab to paclitaxel plus cisplatin in Chinese patients with advanced esophageal squamous cell carcinoma.
 
The effect of deucravacitinib on achievement of ACR-20 in patients with psoriatic arthritis. 
 
Use of camrelizumab, famitinib and nab-paclitaxel in Chinese patients with refractory metastatic immunomodulatory triple-negative breast cancer.
 
The efficacy of gefapixant on the 24-hour coughs per hour average the Phase III COUGH-1 and COUGH-2 trials.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.